Lancet Oncology

Article	Citations
Navigating the complexity: reflections on the development of perioperative cancer treatments	681
Dual therapy in metastatic castration-resistant prostate cancer	649
US FDA proposes stronger laboratory test oversight	562
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	523
Palliative radiotherapy for hepatic cancer pain	487
Driving two chimeric antigen receptors (CARs) in a row to reduce antigen escape in B-cell acute lymphocytic leukaemia	485
Toxicity assessment bias in the PACE-C trial – Authors' reply	427
New national cancer registry for France	426
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX	399
Neurotoxicity-related treatment discontinuations in PRODIGE 51-FFCD-GASTFOX – Authors' reply	386
Olanzapine for chemotherapy-induced nausea and vomiting control	347
Study bolsters concerns about US FDA accelerated drug approvals	323
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer – Authors' reply	315
Combination immunotherapy in chemotherapy in gastric cancer	305
Use of artificial intelligence to enhance detection of nodal metastases	296
The GLOW trial in chronic lymphocytic leukaemia	295
Precision medicine for children with cancer	289
Concern for cancer drugs in USA–EU tariff war	284
Myung-Ju Ahn: battling sexism in medicine and supporting the next generation	269
Combining enzalutamide and [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer	268
IVLBCL mimicking VEXAS syndrome	268
Correction to Lancet Oncol 2022; 23: 1124–26	260
Radiotherapy has a role to play in patients with EGFR-mutated non-small-cell lung cancer in first-line treatment	260
International Radiation Oncology societies Network (IRON): a unified voice in addressing global cancer challenges	247
Determining the optimal use of approved drugs in oncology	239

A new generation of comprehensive precision oncology trials	235
Exploring the link between cancer policies and cancer survival: a comparison of International Cancer Benchmarking Partnership countries	235
Italy to pass law on the right to be forgotten for cancer survivors	232
Antibody–drug conjugates in acute myeloid leukaemia: more research needed	229
Correction to Lancet Oncol 2021; 22: 1081–92	229
Health insurance system in Japan faces risk of politicisation	220
Nomogram-based risk classification for predicting response to metastasis-directed stereotactic body radiotherapy in PSMA PET-staged oligorecurrent prostate cancer (PORTAL): an international, retrospec	217
Clinical benefit and the Trump administration's cancer medicine reforms	213
The silent malignant mesothelioma epidemic: a call to action	207
Real-world challenges and considerations in treating von Hippel-Lindau disease with HIF-2α inhibitors – Authors' reply	205
SANO trial: innovations, risks, and unanswered questions	202
Development of a conceptual framework for an electronic patient-reported outcome (ePRO) system measuring symptoms and impacts of CAR T-cell therapies in patients with haematological malignancies	200
Non-invasive DNA methylation-based testing for the diagnosis of endometrial cancer	194
Carcinogenicity of hepatitis D virus, human cytomegalovirus, and Merkel cell polyomavirus	192
Psychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study	189
Innovation in gynaecological cancer: highlighting global disparities	189
Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial	188
Physical examinations and whole-body imaging versus physical examinations alone during follow-up after radical surgery of stage IIB–C and III cutaneous malignant melanoma (TRIM): an interim analysis o	186
Discontinuation versus continuation of imatinib in patients with advanced gastrointestinal stromal tumours (BFR14): exploratory long-term follow-up of an open-label, multicentre, randomised, phase 3 t	183
Sex disparity in childhood cancer in India: a multi-centre, individual patient data analysis	178
Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas	177
US Surgeon General calls for cancer warning labels on alcohol	177
ALND after neoadjuvant chemotherapy: a call for caution	174
Expanding the ADT-free therapeutic landscape in oligometastatic hormone-sensitive prostate cancer	170
Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised,	169
First Nations cancer inequalities in Canada	169
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1–2, open-label, multicohort trial	164
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase	157
Estimating global cancer survival and mortality from 1990 to 2050: a simulation-based analysis of 17 cancers	156
Cisplatin with veliparib or placebo in metastatic triple-negative breast cancer and BRCA mutation-associated breast cancer (S1416): a randomised, double-blind, placebo-controlled, phase 2 trial	155
Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial	152
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a mult	152
Multinational Association of Supportive Care in Cancer (MASCC) clinical practice guidelines for the prevention and management of acute radiation dermatitis: international Delphi consensus-based recomm	148
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study	143
Mantle cell lymphoma: is it time for risk-adapted treatment?	142
Use of PROMISE criteria on PSMA-PET for prediction of overall survival in prostate cancer	142
Lung cancer rates highest among British Bangladeshi men	139
Cancer on the agenda during IAEA Director General's visit to Chile	139
Balancing clinical benefit and social value: challenges in HTA assessments	136
Daratumumab maintenance in patients with myeloma	134
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update	133
Clearing the radiotherapy backlog: innovation to pave the way	133
Challenges and prospects for cancer treatment in prison settings	133
Common Sense Oncology: including everyone	132
Dobbs v Jackson and fertility preservation among adolescents and young adults with cancer	129
Retroperitoneal fibrosis: carcinoid recurrence or histiocytosis?	129
Importance of clinical research for the UK's 10-year cancer plan	123
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-repo	123
ICGC-ARGO precision medicine: an update on targeted therapy based on longitudinal analysis of tumour heterogeneity and evolution in colorectal cancer	123
Essential anticancer medicines for children: defining what matters most for Europe	123

Decentralised, point-of-care CAR-T for multiple myeloma	122
ESMO Congress 2025	118
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk, early breast cancer – Authors' reply	118
WHO reports health service disruptions due to suspensions of aid	118
Assessment of endpoint definitions in recurrent and metastatic mucosal head and neck squamous cell carcinoma trials: Head and Neck Cancer International Group consensus recommendations	115
Canada's Yukon Territory publishes First Nations Cancer Strategy	115
Focus where it matters: turning insights into advocacy	112
Daratumumab–lenalidomide and the immunosuppressive budget in myeloma – Authors' reply	111
Dobbs v Jackson and access to fertility care among newly diagnosed adolescents and young adults with cancer in the USA	110
2022 ASTRO annual meeting	109
Correction to Lancet Oncol 2023; 24: e242	107
Radiotherapy and conflict: from disruption to expansion and hope	106
Syrian cancer patients regain treatment access in Türkiye	106
The socioeconomic impact of cancer on patients and their relatives: Organisation of European Cancer Institutes task force consensus recommendations on conceptual framework, taxonomy, and research dire	105
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial	105
Findings suggest under-reporting of patient data in US SEER	105
Antimicrobial resistance in patients with haematological malignancies: a scoping review	105
Systemic therapy for brain metastases: a changing landscape	105
De-escalation of adjuvant radiotherapy in HPV-associated oropharyngeal cancer	104
Oral contraceptives and risk of liver cancer	104
Evaluation of progression-free status at 24 months as a surrogate endpoint for overall survival in patients with human papillomavirus-positive oropharyngeal cancer: a retrospective cohort study	103
Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus	101
Performance of the WID-qEC test versus sonography to detect uterine cancers in women with abnormal uterine bleeding (EPI-SURE): a prospective, consecutive observational cohort study in the UK	99
From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit	99
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial	97
The power of words: evaluating the role of qualitative methods in cancer research	97
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAFV600 mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, ra	95
India rolls out HPV vaccination	94
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study	93
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup	93
Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group	92
Beyond monotherapy: chemotherapy-free strategies in first-line advanced non-small-cell lung cancer	92
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial	91
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis	91
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial	90
Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospecti	90
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial	89
Deep-learning-based reconstruction of undersampled MRI to reduce scan times: a multicentre, retrospective, cohort study	89
SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials	89
Promoting cancer prevention through World Cancer Day in Nigeria	88
Olanzapine for chemotherapy-induced nausea and vomiting control – Authors’ reply	88
International consensus on laryngeal preservation strategies in laryngeal and hypopharyngeal cancer	88
Using patient-reported outcomes and health-related quality of life data in regulatory decisions on cancer treatment: highlights from an EMA-EORTC workshop	87
Standardised definitions and diagnostic criteria for extranodal extension detected on histopathological examination in head and neck cancer: Head and Neck Cancer International Group consensus recommen	87
Is upfront full molecular profiling needed in all patients with colorectal cancer in daily practice?	85
Moderately hypofractionated radiotherapy for prostate cancer in an era of SBRT and focal boosting	85
Medical debt of people with cancer in the USA	84
A step closer to the use of [177Lu]Lu-PSMA-617 in metastatic hormone-sensitive prostate cancer	84
AACR Annual Meeting 2023	82
Stereotactic ablative radiotherapy for primary kidney cancer – Authors' reply	82
Pembrolizumab monotherapy for advanced chordoma – Authors' reply	82
Internationally trained doctors in the USA	81
South Africa's new tobacco and e-cigarette control bill	81
Pancytopenia associated with bone marrow infiltration from late relapse of neuroblastoma	81
A red patch on the palate	80
Transforming cancer: behind the scenes at the Crick Institute	80
The importance of preventing occupational cancer	80
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial	79
On a precipice: the UK's broken health-care system	79
Progress in global tobacco control measures	78
Endometrial cancer: the individual approach	78
Outcomes based on risk-adapted adjuvant therapy in postmenopausal women with early breast cancer: a nationwide, prospective cohort study by the Danish Breast Cancer Group	77
Managing immune checkpoint inhibition in transplant recipients	77
Correction to Lancet Oncol 2024; 25: e126–35	76
Full-dose SBRT for the primary tumour in stage III NSCLC: a promising and safe way to selective dose escalation?	74
Radical cystectomy vs trimodality therapy for muscle-invasive bladder cancer: further extensive evaluation needed – Authors' reply	74
Increased extent of neurosurgical resection in IDH-mutated glioma: issues for translation to standard practice	73
Correction to Lancet Oncol 2023; 24: 1181–95	73
Indigenous-led cancer control	72
UK prostate cancer screening trial to include more Black men	72
Efficacy and safety of dabrafenib plus trametinib in adults with differentiated thyroid cancer: a randomised, double-blind, placebo-controlled, phase 3 trial	71
A manifesto for improving cancer detection: four key considerations when implementing innovations across the interface of primary and secondary care	71
Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3	71
Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, singl	70
Adaptive radiotherapy (up to 74 Gy) or standard radiotherapy (66 Gy) for patients with stage III non-small-cell lung cancer, according to [18F]FDG-PET tumour residual uptake at 42 Gy (RTEP7–IFCT-1402)	70
Immunogenicity and safety of a new quadrivalent HPV vaccine in girls and boys aged 9–14 years versus an established quadrivalent HPV vaccine in women aged 15–26 years in India: a randomised, active-co	69
Combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (OPTIMIZE-1): a single-arm, multicentre phase 1b/2 study	69
The prognosis of patients with small cell carcinoma of the cervix: a retrospective study of the SEER database and a Chinese multicentre registry	69
CALLA trial: immunotherapy in locally advanced cervical cancer – Authors' reply	67
Pilot cancer programmes in Côte d'Ivoire, Kenya, and Zimbabwe	67

Changes in cancer diagnoses and stage distribution during the first year of the COVID-19 pandemic in the USA: a cross-sectional nationwide assessment	67
Incorporating absolute effects to enrich interpretation of findings from meta-analyses – Authors' reply	67
American Lung Association calls for expanded insurance coverage for lung cancer screening	66
Challenging cancer through poetry	66
Anticipating the future of cancer care in Trump's America	65
Diagnostic accuracy of risk prediction models in postmenopausal patients with suspected ovarian cancer	64
Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm – Authors' reply	63
Radiotherapy for children and adolescents with early-stage classical Hodgkin lymphoma – Authors' reply	63
18F-NaF PET–CT versus 99mTc SPECT in bone metastasis assessment – Authors' reply	63
US lawmakers call on Biden Administration to lower the price of enzalutamide	63
Quality control and childhood cancer medicines	63
Rezvilutamide for metastatic hormone-sensitive prostate cancer – Authors' reply	63
Sharp increase in patients waiting months for urgent cancer treatment	62
Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE	62
Mitotane: a friend or a foe before cabozantinib treatment in adrenocortical cancer?	61
US Clean Air in the firing line	61
WHO calls for investment in cancer prevention and care within a wider NCD strategy	61
Sharing a personal story behind brain cancer	61
Sharing experiences and forming bonds at the Edinburgh Fringe	61
US cancer research might never recover from proposed Trump funding cuts	61
Management of locally advanced gastric cancer	61
1 in 9 USA cancer diagnoses missed during 2020 COVID-19 pandemic	61
Between the lines: an oncology diary no one assigned	60
Correction to Lancet Oncol 2022; 23: 1297–307	60
Delay to England's National Cancer Plan could cost lives	60
Correction to Lancet Oncol 2023; 24: 91–106	59
Correction to Lancet Oncol 2023; 24: e472–518	59
Correction to Lancet Oncol 2025; 26: 548–49	59
Distant metastasis-free survival with adjuvant pembrolizumab for resected stage IIB or IIC melanoma	58
US drinking water polluted with carcinogenic nitrates	58
US legislation might soon allow easier access to cancer medications	57
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase	57
PSMA-PET research: addressing challenges and prospects – Authors' reply	57
GAIA/CLL13 provides further insight on venetoclax use in chronic lymphocytic leukaemia	57
AKT-targeted triplet therapy in advanced breast cancer	56
Problems with catch-up HPV vaccination after resumption of proactive recommendations	55
San Antonio Breast Cancer Symposium 2025	55
Best practices and novel approaches for the preclinical development of drug–radiotherapy combinations for cancer treatment	54
Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study	54
Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU?	54
Immunotherapy: balancing the risks and benefits	53
Cancer care and outreach in the South Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges	53
Single-dose carboplatin followed by involved-node radiotherapy for stage IIA and stage IIB seminoma (SAKK 01/10): a single-arm, multicentre, phase 2 trial	53
Use of chemotherapy in patients with oesophageal, stomach, colon, rectal, liver, pancreatic, lung, and ovarian cancer: an International Cancer Benchmarking Partnership (ICBP) population-based study	53
PMI faces questions over cigarette marketing and smoke-free commitments	52
Targeting homologous recombination deficiency with intensified chemotherapy versus standard chemotherapy followed by olaparib in stage III breast cancer (SUBITO): an open-label, randomised, controlled	52
Rwanda provides free treatment to all cancer patients	52
New evidence for brain cancer risk after a single paediatric CT scan	51
Qatar national cancer care and research: pioneering strategies for global health excellence	51
ICGC-ARGO precision medicine: an update on immunotherapy response in metastatic head and neck squamous cell carcinoma	50
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-a	49
The changing global landscape of national cancer control plans	49
Correction to Lancet Oncol 2026; 27: 233–42	49
Stereotactic ablative radiotherapy for primary kidney cancer	49
Risks of modelling cancer outcomes when no data exist	49
Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial	49
Long-term overall survival with dual CTLA-4 and PD-L1 or PD-1 blockade and biomarker-based subgroup analyses in patients with advanced non-small-cell lung cancer: a systematic review and reconstructed	49
Palliative radiotherapy versus best supportive care in patients with painful hepatic cancer (CCTG HE1): a multicentre, open-label, randomised, controlled, phase 3 study	49
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised	48
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study	48
HPV vaccine roll-out in Nigeria and Bangladesh	48
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label,	48
Indonesia and the Philippines take steps to control cancer	48
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial	48
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label	48
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-	48
Improved cancer coverage for firefighters in Western Australia	47
Enhancing equity and long-term impact assessments in radiotherapy environmental studies	47
Horizon 2020 evaluation highlights benefit of cross-border research but points to areas for improvement	47
Cancer risk estimates for US EPA-approved alternative plastic-based fuel cause alarm	46
Correction to Lancet Oncol 2022; 23: 416–27	46
BrECADD and fertility: an ongoing concern – Authors' reply	46
Reflections on the PEACE V–STORM trial	46
BrECADD and fertility: an ongoing concern	46
US mRNA cancer vaccine research faces an uncertain future	46
Correction to Lancet Oncol 2024; 25: 744–59	45
Correction to Lancet Oncol 2024; 25: 317–25	45
Correction to Lancet Oncol 2024; 25: 1625–34	45
Uterine cancer mortality and Black women: time to act	44
Carcinogenicity of automotive gasoline and some oxygenated gasoline additives	44
Beyond the count: the unseen foundations of cancer care	44
Cryptic metastatic calcification after radical nephrectomy in a patient with renal cell carcinoma	43
Combination chemo-immunotherapy in advanced oesophageal squamous cell carcinoma	43
US National Firefighter Registry for Cancer shuts down amid layoffs	43
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?	43
Cancer and premature mortality—pushing the frontiers of cancer care	42
Losing my brother, finding myself	42
Cyber-attacks on health-care systems	42
Treatment of Richter transformation—immunotherapy to the rescue?	42
The BREAKING-ICE App: an interactive journey into informative censoring	42
Utilising cancer registry data to monitor cancer burden	42
Capturing the true effect of anti-PD-1 therapy on patients’ health-related quality of life	41
The impact of armed conflict on global patterns of childhood cancer	40
Thank you to The Lancet Oncology's reviewers in 2022	39
The PREOPANC-2 trial in resectable and borderline resectable pancreatic cancer	39